Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas
BackgroundSelect patients with relapsed/refractory aggressive B cell lymphoma may benefit from bridging radiation (bRT) prior to anti-CD19-directed chimeric antigen receptor T cell therapy (CAR-T). Here, we examined patient and treatment factors associated with outcomes and patterns of failure after...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1517348/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832576320807108608 |
|---|---|
| author | Gohar S. Manzar Chelsea C. Pinnix Stephanie O. Dudzinski Kathryn E. Marqueen Elaine E. Cha Lewis F. Nasr Alison K. Yoder Michael K. Rooney Paolo Strati Sairah Ahmed Chijioke Nze Ranjit Nair Luis E. Fayad Michael Wang Loretta J. Nastoupil Jason R. Westin Christopher R. Flowers Sattva S. Neelapu Jillian R. Gunther Bouthaina S. Dabaja Susan Y. Wu Penny Q. Fang |
| author_facet | Gohar S. Manzar Chelsea C. Pinnix Stephanie O. Dudzinski Kathryn E. Marqueen Elaine E. Cha Lewis F. Nasr Alison K. Yoder Michael K. Rooney Paolo Strati Sairah Ahmed Chijioke Nze Ranjit Nair Luis E. Fayad Michael Wang Loretta J. Nastoupil Jason R. Westin Christopher R. Flowers Sattva S. Neelapu Jillian R. Gunther Bouthaina S. Dabaja Susan Y. Wu Penny Q. Fang |
| author_sort | Gohar S. Manzar |
| collection | DOAJ |
| description | BackgroundSelect patients with relapsed/refractory aggressive B cell lymphoma may benefit from bridging radiation (bRT) prior to anti-CD19-directed chimeric antigen receptor T cell therapy (CAR-T). Here, we examined patient and treatment factors associated with outcomes and patterns of failure after bRT and CAR-T.MethodsWe retrospectively reviewed adults with diffuse large B-cell lymphoma (DLBCL) who received bRT prior to axicabtagene ciloleucel, tisagenlecleucel, or lisocabtagene maraleucel between 11/2017-4/2023. Clinical/treatment characteristics, response, and toxicity were extracted. Survival was modeled using Kaplan-Meier or Cox regression models for events distributed over time, or binary logistic regression for disease response. Fisher’s Exact Test or Mann-Whitney U methods were used.ResultsOf 51 patients, 25.5% had bulky disease and 64.7% had Stage III/IV disease at the time of RT. Comprehensive bRT alone to all disease sites was delivered to 51% of patients, and 29.4% were additionally bridged with systemic therapy. Median follow-up was 10.3 months (95% CI: 7.7-16.4). Overall response rate (ORR) was 82.4% at 30 days post-CAR-T infusion. Median overall survival (OS) was 22.1 months (6.6-not reached) and the median progression-free survival (PFS) was 7.4 months (5.5-30). OS/PFS were 80% (66-99)/78% (64-87) at 1-year, and 59% (44-71)/54% (40-67) at 2-years, respectively. Comprehensive RT to all sites of disease correlated with improved PFS and OS, p ≤ 0.04. Additionally, ECOG ≥2 and Stage III/IV disease predicted poor OS (p ≤ 0.02). Disease bulk, IPI ≥3, and non-GCB histology were poor predictors for disease-specific survival (DSS), p<0.05. The latter two, as well as bRT dose of ≤30 Gy predicted worse PFS (p<0.05). Among patients with advanced stage disease, comprehensive bRT to all sites of disease (n=10) was not associated with improved OS and PFS compared to focal bRT (n=23), p>0.17. No difference was seen in bridging RT vs. chemoRT. Twenty-six patients developed relapse (50.9%), of which 46% was in-field. Risk of in-field relapse correlated with bulky disease (OR=7, 95% CI: 1.2-41, p=0.03) and lack of response at 30 day post-CAR-T evaluation (OR=16.8, 95% CI: 1.6-176, p=0.02), but not with bRT dose (p=0.27).ConclusionbRT and CART is a good treatment strategy for select patients with aggressive B cell lymphoma. Comprehensive bRT including all sites of disease is associated with improved outcomes. |
| format | Article |
| id | doaj-art-2458ed1115ae407c92efdaff98890d7f |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-2458ed1115ae407c92efdaff98890d7f2025-01-31T06:39:57ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-01-011610.3389/fimmu.2025.15173481517348Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomasGohar S. Manzar0Chelsea C. Pinnix1Stephanie O. Dudzinski2Kathryn E. Marqueen3Elaine E. Cha4Lewis F. Nasr5Alison K. Yoder6Michael K. Rooney7Paolo Strati8Sairah Ahmed9Chijioke Nze10Ranjit Nair11Luis E. Fayad12Michael Wang13Loretta J. Nastoupil14Jason R. Westin15Christopher R. Flowers16Sattva S. Neelapu17Jillian R. Gunther18Bouthaina S. Dabaja19Susan Y. Wu20Penny Q. Fang21Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesBackgroundSelect patients with relapsed/refractory aggressive B cell lymphoma may benefit from bridging radiation (bRT) prior to anti-CD19-directed chimeric antigen receptor T cell therapy (CAR-T). Here, we examined patient and treatment factors associated with outcomes and patterns of failure after bRT and CAR-T.MethodsWe retrospectively reviewed adults with diffuse large B-cell lymphoma (DLBCL) who received bRT prior to axicabtagene ciloleucel, tisagenlecleucel, or lisocabtagene maraleucel between 11/2017-4/2023. Clinical/treatment characteristics, response, and toxicity were extracted. Survival was modeled using Kaplan-Meier or Cox regression models for events distributed over time, or binary logistic regression for disease response. Fisher’s Exact Test or Mann-Whitney U methods were used.ResultsOf 51 patients, 25.5% had bulky disease and 64.7% had Stage III/IV disease at the time of RT. Comprehensive bRT alone to all disease sites was delivered to 51% of patients, and 29.4% were additionally bridged with systemic therapy. Median follow-up was 10.3 months (95% CI: 7.7-16.4). Overall response rate (ORR) was 82.4% at 30 days post-CAR-T infusion. Median overall survival (OS) was 22.1 months (6.6-not reached) and the median progression-free survival (PFS) was 7.4 months (5.5-30). OS/PFS were 80% (66-99)/78% (64-87) at 1-year, and 59% (44-71)/54% (40-67) at 2-years, respectively. Comprehensive RT to all sites of disease correlated with improved PFS and OS, p ≤ 0.04. Additionally, ECOG ≥2 and Stage III/IV disease predicted poor OS (p ≤ 0.02). Disease bulk, IPI ≥3, and non-GCB histology were poor predictors for disease-specific survival (DSS), p<0.05. The latter two, as well as bRT dose of ≤30 Gy predicted worse PFS (p<0.05). Among patients with advanced stage disease, comprehensive bRT to all sites of disease (n=10) was not associated with improved OS and PFS compared to focal bRT (n=23), p>0.17. No difference was seen in bridging RT vs. chemoRT. Twenty-six patients developed relapse (50.9%), of which 46% was in-field. Risk of in-field relapse correlated with bulky disease (OR=7, 95% CI: 1.2-41, p=0.03) and lack of response at 30 day post-CAR-T evaluation (OR=16.8, 95% CI: 1.6-176, p=0.02), but not with bRT dose (p=0.27).ConclusionbRT and CART is a good treatment strategy for select patients with aggressive B cell lymphoma. Comprehensive bRT including all sites of disease is associated with improved outcomes.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1517348/fullCAR-Tchimeric antigen receptorradiation therapybridging RTDLBCL |
| spellingShingle | Gohar S. Manzar Chelsea C. Pinnix Stephanie O. Dudzinski Kathryn E. Marqueen Elaine E. Cha Lewis F. Nasr Alison K. Yoder Michael K. Rooney Paolo Strati Sairah Ahmed Chijioke Nze Ranjit Nair Luis E. Fayad Michael Wang Loretta J. Nastoupil Jason R. Westin Christopher R. Flowers Sattva S. Neelapu Jillian R. Gunther Bouthaina S. Dabaja Susan Y. Wu Penny Q. Fang Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas Frontiers in Immunology CAR-T chimeric antigen receptor radiation therapy bridging RT DLBCL |
| title | Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas |
| title_full | Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas |
| title_fullStr | Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas |
| title_full_unstemmed | Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas |
| title_short | Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas |
| title_sort | outcomes with bridging radiation therapy prior to chimeric antigen receptor t cell therapy in patients with aggressive large b cell lymphomas |
| topic | CAR-T chimeric antigen receptor radiation therapy bridging RT DLBCL |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1517348/full |
| work_keys_str_mv | AT goharsmanzar outcomeswithbridgingradiationtherapypriortochimericantigenreceptortcelltherapyinpatientswithaggressivelargebcelllymphomas AT chelseacpinnix outcomeswithbridgingradiationtherapypriortochimericantigenreceptortcelltherapyinpatientswithaggressivelargebcelllymphomas AT stephanieodudzinski outcomeswithbridgingradiationtherapypriortochimericantigenreceptortcelltherapyinpatientswithaggressivelargebcelllymphomas AT kathrynemarqueen outcomeswithbridgingradiationtherapypriortochimericantigenreceptortcelltherapyinpatientswithaggressivelargebcelllymphomas AT elaineecha outcomeswithbridgingradiationtherapypriortochimericantigenreceptortcelltherapyinpatientswithaggressivelargebcelllymphomas AT lewisfnasr outcomeswithbridgingradiationtherapypriortochimericantigenreceptortcelltherapyinpatientswithaggressivelargebcelllymphomas AT alisonkyoder outcomeswithbridgingradiationtherapypriortochimericantigenreceptortcelltherapyinpatientswithaggressivelargebcelllymphomas AT michaelkrooney outcomeswithbridgingradiationtherapypriortochimericantigenreceptortcelltherapyinpatientswithaggressivelargebcelllymphomas AT paolostrati outcomeswithbridgingradiationtherapypriortochimericantigenreceptortcelltherapyinpatientswithaggressivelargebcelllymphomas AT sairahahmed outcomeswithbridgingradiationtherapypriortochimericantigenreceptortcelltherapyinpatientswithaggressivelargebcelllymphomas AT chijiokenze outcomeswithbridgingradiationtherapypriortochimericantigenreceptortcelltherapyinpatientswithaggressivelargebcelllymphomas AT ranjitnair outcomeswithbridgingradiationtherapypriortochimericantigenreceptortcelltherapyinpatientswithaggressivelargebcelllymphomas AT luisefayad outcomeswithbridgingradiationtherapypriortochimericantigenreceptortcelltherapyinpatientswithaggressivelargebcelllymphomas AT michaelwang outcomeswithbridgingradiationtherapypriortochimericantigenreceptortcelltherapyinpatientswithaggressivelargebcelllymphomas AT lorettajnastoupil outcomeswithbridgingradiationtherapypriortochimericantigenreceptortcelltherapyinpatientswithaggressivelargebcelllymphomas AT jasonrwestin outcomeswithbridgingradiationtherapypriortochimericantigenreceptortcelltherapyinpatientswithaggressivelargebcelllymphomas AT christopherrflowers outcomeswithbridgingradiationtherapypriortochimericantigenreceptortcelltherapyinpatientswithaggressivelargebcelllymphomas AT sattvasneelapu outcomeswithbridgingradiationtherapypriortochimericantigenreceptortcelltherapyinpatientswithaggressivelargebcelllymphomas AT jillianrgunther outcomeswithbridgingradiationtherapypriortochimericantigenreceptortcelltherapyinpatientswithaggressivelargebcelllymphomas AT bouthainasdabaja outcomeswithbridgingradiationtherapypriortochimericantigenreceptortcelltherapyinpatientswithaggressivelargebcelllymphomas AT susanywu outcomeswithbridgingradiationtherapypriortochimericantigenreceptortcelltherapyinpatientswithaggressivelargebcelllymphomas AT pennyqfang outcomeswithbridgingradiationtherapypriortochimericantigenreceptortcelltherapyinpatientswithaggressivelargebcelllymphomas |